OnKure (OKUR) director receives 15,300 stock options at $4.14 strike price
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
OnKure Therapeutics director Liam Ratcliffe received a new stock option grant as part of compensation. The award covers 15,300 options to buy Class A common stock at an exercise price of $4.14 per share, expiring on March 30, 2036.
These options vest over time: 1/36 of the grant vests on April 30, 2026 and 1/36 on the last day of each following month, as long as he continues as a service provider. After this grant, he holds 15,300 stock options directly from this award.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ratcliffe Liam
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 15,300 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 15,300 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 15,300 options
Exercise price: $4.14 per share
Expiration date: March 30, 2036
+3 more
6 metrics
Stock options granted
15,300 options
Grant to director Liam Ratcliffe on March 31, 2026
Exercise price
$4.14 per share
Strike price for new options
Expiration date
March 30, 2036
Option term end date
Underlying shares
15,300 shares
Class A common stock underlying the options
Vesting schedule
1/36 monthly
Starts April 30, 2026, then last day of each month
Post-grant derivative holdings
15,300 options
Total options held from this award after the transaction
Key Terms
Stock Option (right to buy), Class A Common Stock, exercise price, vesting
4 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
Class A Common Stock financial
"underlying_security_title: "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
exercise price financial
"conversion_or_exercise_price: "4.1400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
""1/36th of the shares subject to the option shall vest""
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What did OnKure Therapeutics (OKUR) director Liam Ratcliffe report on this Form 4?
Liam Ratcliffe reported receiving a stock option grant for 15,300 shares of Class A common stock at a $4.14 exercise price. This award is compensation-related, not an open‑market purchase or sale, and increases his derivative-based exposure to OnKure shares.
What is the exercise price and expiration for Liam Ratcliffe’s OnKure (OKUR) options?
The options have a $4.14 per share exercise price and expire on March 30, 2036. This means Ratcliffe can buy shares at $4.14, once vested, any time before the March 2036 expiration date, subject to plan and award terms.
How do Liam Ratcliffe’s OnKure (OKUR) options vest over time?
The options vest in monthly installments over three years. One‑thirty‑sixth vests on April 30, 2026, and one‑thirty‑sixth vests on the last day of each subsequent month, contingent on Ratcliffe continuing as a service provider through each applicable vesting date.